Scientists have developed a small peptide that they say can reverse some of the cognitive repercussions of neurodegenerative and potentially trauma-related brain disorders such as Alzheimer’s disease, by increasing synaptogenesis. The peptide, called dihexa, is a stabilized derivative of angiotensin IV (AngIV), a peptide that, together with some of its analogs, is recognized as a precognitive agent that could feasibly be used as a treatment for neurodegenerative diseases, but in its native form it can’t cross the blood-brain barrier and isn’t stable enough to have any utility in a clinical setting.
No comments:
Post a Comment